Allergan, Mimetogen partner to develop tavilermide topical dry eye treatment
As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal
VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.
The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD. Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution